EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine

Saif Khan iD, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza iD, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani

Cells · 2024

DOI: 10.3390/cells13242126 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Saif Khan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Dental and Medical Sciences, College of Dentistry, University of Ha'il, Ha'il 55473, Saudi Arabia. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Camptothecin, Immunoconjugates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Deanship at the University of Ha'il, Saudi Arabia, Scientific Research Deanship at the University of Ha’il, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. Antibody–drug conjugates (ADCs) like sacituzumab govitecan-hziy (SG) represent a significant advancement. SG combines SN-38, an irinotecan derivative, with a Trop-2-targeting antibody via a pH-sensitive linking moiety, achieving a good drug:antibody ratio. In a phase I-II study involving metastatic TNBC (mTNBC) individuals, SG achieved an overall response rate of 33.3% and a median response period of 7.7 months. The phase III ASCENT trial demonstrated SG’s efficacy in relapsed or refractory TNBC, improving median progression-free survival and median overall survival compared to chemotherapy. Common side effects include neutropenia, nausea, and fatigue. This article highlights the clinical potential, pharmacokinetics, safety profile, and resistance mechanisms of SG along with key ongoing clinical trials, emphasizing its role in managing refractory mTNBC, especially in third-line therapy. The review also discusses current strategies for managing adverse reactions and sequencing ADC treatments in clinical practice, along with the predicted basis of resistance. The optimal sequencing of SG relative to other ADCs, such as trastuzumab deruxtecan or T-DXd, remains an evolving question, especially as newer agents with distinct mechanisms of action and safety profiles enter the field. Further research is essential to establish evidence-based strategies for sequencing SG and addressing disease progression post-ADC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatesPrecision MedicineHumansFemaleDrug Resistance, Neoplasm

Stichwörter der Autor:innen

ADC sequencingantibody–drug conjugatesneutropeniaresistancesacituzumab govitecantriple-negative breast cancer (TNBC)

Substanzen

sacituzumab govitecanAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugates

Autor:innen und Institutionen

  • Department of Basic Dental and Medical Sciences, College of Dentistry, University of Ha'il, Ha'il 55473, Saudi Arabia.
  • Department of Preventive Dental Sciences, College of Dentistry, University of Ha'il, Ha'il 55473, Saudi Arabia.
  • Department of Biology, College of Science, University of Ha'il, Ha'il 55473, Saudi Arabia.
  • Centre of Research Impact and Outcome, Chitkara University, Rajpura 140401, India.
  • Chitkara Center for Research and Development, Chitkara University, Baddi 174103, India.
  • Department of Mechanical Engineering, Institute of Aeronautical Engineering, Hyderabad 500043, India.

ORCID-Profile: Saif Khan, Shadab Mirza

Förderung

  • Scientific Research Deanship at the University of Ha'il, Saudi Arabia
  • Scientific Research Deanship at the University of Ha’il, Saudi Arabia

Zitieren

APA

Khan, S., Jandrajupalli, S. B., Bushara, N. Z. A., Raja, R. D. P., Mirza, S., Sharma, K., Verma, R., Kumar, A., & Lohani, M. (2024). Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine. Cells. https://doi.org/10.3390/cells13242126

Vancouver

Khan S, Jandrajupalli SB, Bushara NZA, Raja RDP, Mirza S, Sharma K, et al. Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine. Cells. 2024. doi:10.3390/cells13242126

BibTeX
@article{Khan2024,
  author = {Khan, Saif and Jandrajupalli, Suresh Babu and Bushara, Nashwa Zaki Ali and Raja, Rama Devi Patel and Mirza, Shadab and Sharma, Kuldeep and Verma, Rajan and Kumar, Ashish and Lohani, Mohtashim},
  title = {Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13242126}
}
Kostenlos starten →